Alchemyca Biotech | $2,500,000 | (Nov 22, 2024)
Clean Skin Club | $32,000,000 | (Nov 22, 2024)
Iontra Inc | $45,000,000 | (Nov 22, 2024)
Antiva Biosciences, Inc.
United States
- South San Francisco, California
- 27/04/2023
- Series E
- $53,000,000
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3).
The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
- Industry Biotechnology Research
- Website https://antivabio.com/
- LinkedIn https://www.linkedin.com/company/antiva-biosciences-inc/people/
Related People
Karl HostetlerFounder
United States -
San Diego County, California
Medical Specialties: Board Certified Internal Medicine and Endocrinology & Metabolism
Medicinal Chemistry
Translational Research
Drug Discovery
Antiviral drugs
Lighthouse (UK) | $370,000,000 | (Nov 22, 2024)
Shinami | $5,645,000 | (Nov 22, 2024)
Four Growers, Inc. | $9,000,000 | (Nov 21, 2024)
Flywl | $7,000,000 | (Nov 21, 2024)
Magma Math | $40,000,000 | (Nov 21, 2024)
Prompt Security | $18,000,000 | (Nov 21, 2024)
Konsileo | $10,122,225 | (Nov 21, 2024)